A key evolution in cell and gene therapy is the significant effort to target tissues beyond the liver, such as the lungs, kidneys, pancreas, and CNS. While a major technical and clinical challenge, this expansion is critical for moving beyond traditional ex vivo therapies and treating a wider range of diseases.

Unlike external machines, implanting parts internally triggers the body's powerful defenses. The immune system attacks foreign objects, and blood forms clots around non-native surfaces. These two biological responses are the biggest design hurdles for internal replacement parts, problems that external devices like dialysis machines don't face.

Prior therapeutic strategies were flawed. Symptomatic treatments squeeze more function from the few remaining neurons until they also die. Disease-modifying drugs, like antibodies, are often ineffective because the blood-brain barrier allows less than 0.1% to reach the brain.

Regenerative cell therapies are emerging as a disease-modifying option for Parkinson's. Unlike previous attempts with fetal cells, new therapies use homogenous cell populations. This allows for precise control over the differentiation stage, enhancing safety and the potential for durable efficacy by replacing lost neurons.

Advanced cell therapy isn't just about replacing lost cells. Transplanted, genetically engineered cells can be programmed to produce and secrete therapeutics locally. This turns them into a delivery platform that solves the critical challenge of the blood-brain barrier for large molecules.

Standard post-thaw viability tests are misleading for cell therapies. DMSO can cause profound, non-lethal damage by altering gene expression, inducing differentiation in stem cells, and impairing T-cell function. Cells may be 'alive' but therapeutically impotent, a risk not captured by simple viability metrics.

Instead of focusing on symptomatic relief, Gain Therapeutics' molecule corrects a misfolded enzyme. This restores the enzyme's ability to break down toxic lipids that accumulate in nerve cells, addressing a root cause of cell damage and disease progression, rather than just managing symptoms like dopamine loss.

While small molecules might eventually cure other conditions, brain diseases are uniquely defined by the physical loss of cells. Therefore, cell replacement therapy isn't just another approach; it's the most logical and potentially only curative long-term solution.

New single-cell atlases of Parkinson's brains show that biological pathways are activated differently depending on the brain region and disease stage. This adds a critical layer of complexity, implying that a "disease-modifying" drug may need to be targeted to specific cell types at specific times, complicating clinical development.